All women over the age of 13 need annual gynecological examinations. This company offers a device that allows doctors to detect cervical cancers earlier, and with less discomfort to their patients as well. It is a telling example of how small innovations can lend huge and enduring value to stocks.
The company is based in Chicago, IL. The early May 2008 stock price is just $2.90, and the market capitalization is around $118 million. No institution has invested in the stock as yet. It is a tempting opportunity to be a part of this dynamic corporation.
Though the company’s focus is on gynecology, it goes beyond creative diagnostic tools to develop novel drug delivery systems as well. The latter relates to local application of approved drugs to the cervix and the immediate surrounding areas. Surgery has been the only option for lesions in this part of female anatomy until now. The new device developed by the company could bring relief and better health care to innumerable women worldwide.
A low cost, integrated microscope platform for imaging and proprietary biochemical assays are other product lines which this company has developed. They combine to offer doctors significant new advantages in timely diagnoses of serious diseases of women. The company has an especially noteworthy role in the early diagnosis of cervical cancer.
The molecular diagnostics market, in which this company operates, is expected to grow rapidly in the near future. Global demand should cross $6 billion by 2015, while more than 40% of the present market is in the United States alone.
Let us hear your thoughts below: